• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Pancreatic cancer cohort

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Chung, H.
    Villanueva, L.
    Graham, Donna
    Saada-Bouzid, E.
    Ghori, R.
    Kubiak, P.
    Gumuscu, B.
    Lerman, N
    Gomez-Roca, C.
    Affiliation
    Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center,Yonsei University College of Medicine, Seoul, South Korea
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background:Over the past few decades, the global incidence and mortality ratesassociated with pancreatic cancer have continued to increase. Pancreatic cancer has aparticularly poor prognosis, with a 5-year survival rate of only approximately 5%. Patientswith pancreatic cancer generally respond poorly to chemotherapy, and their treatmentoptions in the second-line or later setting are limited. In two multicohort, open-labeltrials, including the phase 1b/2 KEYNOTE-146 (NCT02501096) and phase 2 LEAP-005(NCT03797326) studies, the combination of theantiangiogenic multikinase inhibitorlenvatinib and the anti‒PD-1 monoclonal antibody pembrolizumab demonstratedpromising antitumor activity with a manageable safety profile in patients with previouslytreated (both studies) and untreated (KEYNOTE-146) histologically or cytologicallyconfirmed metastatic (both studies) and/or unresectable (LEAP-005) solid tumors. In theLEAP-005 trial, benefit was seen in cohorts with glioblastoma multiforme and biliary tractcancer (second-line treatment), triple-negative breast cancer (second- and third-linetreatment), gastric and colorectal cancer (third-line treatment), and ovarian cancer(fourth-line treatment). Based on these encouraging results and the unmet need forpatients with pancreatic cancer, the LEAP-005 protocol was amended to include apancreatic cancer cohort. Here we describe the LEAP-005 trial design for this cohort.Trial design:Eligible patients are aged 18 years with histologically or cytologicallyconfirmed metastatic pancreatic ductal adenocarcinoma and have received 1 or 2prior lines of therapy (including 1 platinum- or gemcitabine-containing regimen),have measurable disease per RECIST version 1.1, have ECOG performance status of0 or 1, and provide a tissue sample for evaluation of PD-L1 expression. Patientsreceive lenvatinib 20 mg once daily plus pembrolizumab 200 mg Q3W for up to 35cycles of pembrolizumab (approximately 2 years) or until confirmed disease pro-gression, unacceptable toxicity, or withdrawal of consent. Treatment with lenvatinibcan continue beyond 2 years in patients experiencing clinical benefit. The primaryendpoints are ORR (per RECIST version 1.1 by blinded independent central review)and safety. The primary safety endpoints are treatment-emergent AEs, serious AEs,and discontinuations due to AEs, with AEs graded using National Cancer InstituteCommon Terminology Criteria for Adverse Events version 4.0. Secondary endpointsinclude disease control rate (comprising CR, PR, and SD), duration of response, PFS,and OS. Health-related quality of life is assessed using validated patient-reportedoutcome instruments including the European Organisation for the Research andTreatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30). Tumorimaging is performed Q9W from treatment initiation for 54 weeks, then Q12W toweek 102, and Q24W thereafter. PD-L1 expression is assessed by a central laboratoryusing PD-L1 IHC 22C3 (Agilent Technologies, Carpinteria, CA). The pancreatic cancercohort began enrollment in March 2021. An interim analysis is planned when thefirst30 patients enrolled have been followed up for approximately 6 months.
    Citation
    Chung H, Villanueva L, Graham D, Saada-Bouzid E, Ghori R, Kubiak P, et al. P-139 A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Pancreatic cancer cohort. Annals of Oncology. 2021 Jul;32:S146.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624429
    DOI
    10.1016/j.annonc.2021.05.194
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.05.194
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.05.194
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.